20 May 2025

STEMI Stents, scaffolds and DCB

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

Sponsored by SMT (Sahajanand Medical Technologies)

Anchorperson: P. Serruys

Spokesperson: Y. Onuma

Summary

Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get a preview of upcoming randomised trials comparing Supraflex with current standards in triple vessel disease. Stay ahead with insights on how Supraflex is shaping interventional cardiology today and into 2025.

Learning Objectives

To understand the coverage of thin strut sirolimus DES in small vs. large vessel, in diabetes, and in STEMI with OCT analysis
To understand the performance of the Supraflex stent for high-risk patients such as high bleeding risk or the elderly
To preview the anticipated outcomes of two major randomised trials in patients with triple vessel disease, with or without diabetes

Speaker

P. Serruys

Welcome and session objectives

Download presentation

Speaker

T. Y. Tsai

Two-year follow-up of live case performed in Toulouse: left main bifurcation guided by coronary CT angiography and OCT

Download presentation

Speaker

A. Abhyankar

The coverage of thin strut sirolimus DES in small vs. large vessel, in diabetes, and in STEMI with OCT analysis

Download presentation

Speaker

G. Campo

Evidence of Supraflex in high bleeding risk patients: the EARTH HBR study: a pooled analysis of nearly 1000 patients with one-month DAPT from the FIRE, COMPARE60/80, Cruz HBR studies